Merriman Wealth Management’s Biocept, Inc. BIOC Stock Holding History

Merriman Wealth Management’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-77	Closed	-$7K	–	215
2019 Q4	$7K	Buy	+77	New	+$13.3K	﹤0.01%	182
2017 Q1	–	Sell	-2	Closed	-$12K	–	150
2016 Q4	$12K	Buy	+2	New	+$16.7K	﹤0.01%	123
2016 Q3	–	Sell	-1	Closed	-$12K	–	149
2016 Q2	$12K	Buy	+1	New	+$24.2K	﹤0.01%	107

Other funds holding BIOC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Merriman Wealth Management's BIOC Position: Q1 2020 in Review

Merriman Wealth Management sold out of Biocept, Inc. (BIOC) in Q1 2020, closing a stake of 77 shares — an estimated $7K sold.

Merriman Wealth Management first reported a position in BIOC in Q2 2016 and held it in 3 quarters. The position peaked at $12K in Q4 2016. 19 funds tracked by Wall St. Rank hold BIOC as of Q1 2020.

Merriman Wealth Management reported no remaining Biocept, Inc. position as of Q1 2020 after selling out during the quarter.
Merriman Wealth Management sold 77 Biocept, Inc. shares in Q1 2020, an estimated $7K.
Merriman Wealth Management first reported a position in Biocept, Inc. in Q2 2016 and held it in 3 quarters.
Merriman Wealth Management's Biocept, Inc. position peaked at $12K in Q4 2016.
19 funds tracked by Wall St. Rank held Biocept, Inc. as of Q1 2020.

Based on Merriman Wealth Management's 13F filing for Q1 2020, filed 22 Apr 2020.